FDA-approved nirsevimab-alip helps protect newborns and young children from RSV.

Published Date: 20 Jul 2023

The approval comes after the FDA Antimicrobial Drugs Advisory Committee unanimously endorsed nirsevimab-alip's favorable benefit-risk profile for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

4.

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot